April 23, 2026
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First Patient Dosed
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First...
Read More
April 7, 2026
CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma
CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination...
Read More